Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model

Biological Chemistry

Volumn 389, Issue 8, 2008, Pages 1067-1074

  Schurigt, Uta ^a   Sevenich, Lisa ^a   Vannier, Corinne ^a   Gajda, Mieczyslaw ^b   Schwinde, Anne ^a   Werner, Fee ^a   Stahl, Andreas ^c   Von Elverfeldt, Dominik ^a   Becker, Anne Katrin ^a   Bogyo, Matthew ^d   Peters, Christoph ^a   Reinheckel, Thomas ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pharmacokinetics; Protease inhibitor; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN; COLLAGEN TYPE 1; JPM OET; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; EARLY CANCER; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; KIDNEY; LIVER; LUNG METASTASIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SPHEROID CELL; TRANSGENIC MOUSE; TUMOR CELL; TUMOR VOLUME;

MOUSE MAMMARY TUMOR VIRUS; MUS; MUS MUSCULUS;

EID: 50849133244     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.115     Document Type: Conference Paper

References (28)

1. Arkona, C. and Wiederanders, B. (1996). Expression, subcellular distribution and plasma membrane binding of catwhepsin B and gelatinases in bone metastatic tissue. Biol. Chem. 377, 695-702.
2. Authier, F., Metioui, M., Bell, A.W., and Mort, J.S. (1999). Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B. J. Biol. Chem. 274, 33723-33731.
3. Bell-McGuinn, K.M., Garfall, A.L., Bogyo, M., Hanahan, D., and Joyce, J.A. (2007). Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 67, 7378-7385.
4. Downs, L.S. Jr, Lima, P.H., Bliss, R.L., and Blomquist, C.H. (2005). Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer. J. Soc. Gynecol. Invest. 12, 539-544.
5. Elston, C.W. and Ellis, I.O. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19, 403-410.
6. Felbor, U., Kessler, B., Mothes, W., Goebel, H.H., Ploegh, H.L., Bronson, R.T., and Olsen, B.R. (2002). Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl. Acad. Sci. USA 99, 7883-7888.
7. Frese, K.K. and Tuveson, D.A. (2007). Maximizing mouse cancer models. Nat. Rev. Cancer 7, 645-658.
8. Gocheva, V. and Joyce, J.A. (2007). Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6, 60-64.
9. Gocheva, V., Zeng, W., Ke, D., Klimstra, D., Reinheckel, T., Peters, C., Hanahan, D., and Joyce, J.A. (2006). Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20, 543-556.
10. Gottesman, M.M., Fojo, T., and Bates, S.E. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58.
11. Goulet, B., Sansregret, L., Leduy, L., Bogyo, M., Weber, E., Chauhan, S.S., and Nepveu, A. (2007). Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation. Mol. Cancer Res. 5, 899-907.
12. Guy, C.T., Cardiff, R.D., and Muller, W.J. (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954-961.
13. Joyce, J.A., Baruch, A., Chehade, K., Meyer-Morse, N., Giraudo, E., Tsai, F.Y., Greenbaum, D.C., Hager, J.H., Bogyo, M., and Hanahan, D. (2004). Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453.
14. Lechner, A.M., Assfalg-Machleidt, I., Zahler, S., Stoeckelhuber, M., Machleidt, W., Jochum, M., and Nagler, D.K. (2006). RGD-dependent binding of procathepsin X to integrin ab3 mediates cell-adhesive properties. J. Biol. Chem. 281, 39588-39597.
15. Liotta, L.A. and Kohn, E.C. (2001). The microenvironment of the tumour-host interface. Nature 411, 375-379.
16. Mai, J., Finley, R.L. Jr, Waisman, D.M., and Sloane, B.F. (2000). Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J. Biol. Chem. 275, 12806-12812.
17. Meara, J.P. and Rich, D.H. (1996). Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors. J. Med. Chem. 39, 3357-3366.
18. Mohamed, M.M. and Sloane, B.F. (2006). Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 6, 764-775.
19. Nakagawa, T., Roth, W., Wong, P., Nelson, A., Farr, A., Deussing, J., Villadangos, J.A., Ploegh, H., Peters, C., and Rudensky, A.Y. (1998). Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 280, 450-453.
20. Petermann, I., Mayer, C., Stypmann, J., Biniossek, M.L., Tobin, D.J., Engelen, M.A., Dandekar, T., Grune, T., Schild, L., Peters, C., and Reinheckel, T. (2006). Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice. FASEB J. 20, 1266-1268.
21. Reinheckel, T., Hagemann, S., Dollwet-Mack, S., Martinez, E., Lohmuller, T., Zlatkovic, G., Tobin, D.J., Maas-Szabowski, N., and Peters, C. (2005). The lysosomal cysteine protease cathepsin L regulates keratinocyte proliferation by control of growth factor recycling. J. Cell Sci. 118, 3387-3395.
22. Sadaghiani, A.M., Verhelst, S.H., Gocheva, V., Hill, K., Majerova, E., Stinson, S., Joyce, J.A., and Bogyo, M. (2007). Design, synthesis, and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain-family cysteine proteases. Chem. Biol. 14, 499-511.
23. Sevenich, L., Pennacchio, L.A., Peters, C., and Reinheckel, T. (2006). Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B/L double-deficient mice. Biol. Chem. 387, 885-891.
24. Spira, D., Stypmann, J., Tobin, D.J., Petermann, I., Mayer, C., Haggemann, S., Vasiljeva, O., Gunther, T., Schule, R., Peters, C., and Reinheckel, T. (2007). Cell type-specific functions of the lysosomal protease cathepsin L in the heart. J. Biol. Chem. 282, 37045-37052.
25. Urbich, C., Heeschen, C., Aicher, A., Sasaki, K., Bruhl, T., Farhadi, M.R., Vajkoczy, P., Hofmann, W.K., Peters, C., Pennacchio, L.A., et al. (2005). Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat. Med. 11, 206-213.
26. Vasiljeva, O. and Turk, B. (2008). Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion. Biochimie 90, 380-386.
27. Vasiljeva, O., Papazoglou, A., Kruger, A., Brodoefel, H., Korovin, M., Deussing, J., Augustin, N., Nielsen, B.S., Almholt, K., Bogyo, M., et al. (2006). Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 66, 5242-5250.
28. Vasiljeva, O., Reinheckel, T., Peters, C., Turk, D., Turk, V., and Turk, B. (2007). Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 13, 385-401.